Apogee Therapeutics, Inc. (APGE) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Apogee has multiple imminent clinical catalysts (APEX Phase 2 Part B 16‑week topline in Q2 2026 and Phase 3 AD start H2 2026) on top of strong 52‑week APEX Part A durability data released 2026‑03‑23 and a ~$350m equity raise at $70 that extends cash runway into 2028; with 21‑day ROC ~+10.8% and price ~9% above its 21‑day SMA, the setup is a classic event‑driven biotech hot idea.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • High liquidity • Zero revenue • Persistent cash burn APGE has a very strong liquidity and low-leverage balance sheet but is pre-revenue, burning cash with large operating losses and reliant on external financing.
Price Behavior
Key Price Behavior Insights: • Strong momentum • Recent exhaustion • Pullback risk Support Level: $78–$79; secondary $73 Resistance Level: $84.17–$84.34 Price has rallied ~19% over the last month from $70.92 to $84.34, sitting ~16.5% above the SMA last month (~$75) — bullish momentum is intact but the move is extended near highs (84.17–84.34) with pullback risk toward $78–$75.
Sentiment & News
Key News Insights: • Durable maintenance • Major financing • Near-term catalysts Apogee reported robust 52-week Phase 2 maintenance data for zumilokibart, completed a ~$403M equity raise that coincided with a 52-week high and bullish analyst commentary, and highlighted near-term Part B and potential Phase 3 catalysts.
AI Summary
APGE's $403M raise removes near‑term financing as the dominant risk and reframes the stock as an execution story—monitor Part B 16‑week induction data and the planned H2‑2026 Phase‑3 start (cash runway into H2‑2028) as the primary catalysts that will drive valuation. If Part B misses or Phase‑3 timing slips, dilution and rapid downside are likely despite the stronger balance sheet.
Description
Apogee Therapeutics is a biotechnology firm developing biologic therapies for atopic dermatitis, COPD and related inflammatory and immunological conditions. Its lead programs are subcutaneously administered, extended half-life monoclonal antibodies advancing in AD and COPD, with additional earlier-stage antibody programs for AD. The company was founded in 2022 and is headquartered in Waltham, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 26 | Apr 2 | APGE | Apogee Therapeutics, Inc. | Apogee has multiple imminent clinical catalysts (APEX Phase 2 Part B 16‑week topline in Q2 2026 and Phase 3 AD start H2 2026) on top of strong 52‑week APEX Part A durability data released 2026‑03‑23 and a ~$350m equity raise at $70 that extends cash runway into 2028; with 21‑day ROC ~+10.8% and price ~9% above its 21‑day SMA, the setup is a classic event‑driven biotech hot idea. | Closed | +7.5% |